DBV Technologies S.A. (DBV) - Net Assets
Based on the latest financial reports, DBV Technologies S.A. (DBV) has net assets worth €207.90 Million EUR (≈ $243.06 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€266.40 Million ≈ $311.45 Million USD) and total liabilities (€58.50 Million ≈ $68.39 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore DBV total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €207.90 Million |
| % of Total Assets | 78.04% |
| Annual Growth Rate | 20.79% |
| 5-Year Change | 70.02% |
| 10-Year Change | -37.0% |
| Growth Volatility | 138.98 |
DBV Technologies S.A. - Net Assets Trend (2007–2025)
This chart illustrates how DBV Technologies S.A.'s net assets have evolved over time, based on quarterly financial data. Check DBV goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for DBV Technologies S.A. (2007–2025)
The table below shows the annual net assets of DBV Technologies S.A. from 2007 to 2025. For live valuation and market cap data, see DBV Technologies S.A. (DBV) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €168.79 Million ≈ $197.33 Million |
+516.31% |
| 2024-12-31 | €27.39 Million ≈ $32.02 Million |
-80.46% |
| 2023-12-31 | €140.19 Million ≈ $163.89 Million |
-27.92% |
| 2022-12-31 | €194.50 Million ≈ $227.39 Million |
+95.92% |
| 2021-12-31 | €99.27 Million ≈ $116.06 Million |
-60.61% |
| 2020-12-31 | €252.01 Million ≈ $294.62 Million |
+15.57% |
| 2019-12-31 | €218.05 Million ≈ $254.92 Million |
+31.53% |
| 2018-12-31 | €165.78 Million ≈ $193.81 Million |
-9.35% |
| 2017-12-31 | €182.88 Million ≈ $213.81 Million |
-31.74% |
| 2016-12-31 | €267.90 Million ≈ $313.21 Million |
-30.28% |
| 2015-12-31 | €384.24 Million ≈ $449.21 Million |
+110.86% |
| 2014-12-31 | €182.22 Million ≈ $213.04 Million |
+145.96% |
| 2013-12-31 | €74.09 Million ≈ $86.61 Million |
+10.84% |
| 2012-12-31 | €66.84 Million ≈ $78.15 Million |
+237.82% |
| 2011-12-31 | €19.79 Million ≈ $23.13 Million |
+130.96% |
| 2010-12-31 | €8.57 Million ≈ $10.02 Million |
+86.40% |
| 2009-12-31 | €4.60 Million ≈ $5.37 Million |
+145.25% |
| 2008-12-31 | €1.87 Million ≈ $2.19 Million |
-66.74% |
| 2007-12-31 | €5.63 Million ≈ $6.59 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to DBV Technologies S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39317586200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €26.92 Million | 15.95% |
| Other Comprehensive Income | €-5.43 Million | -3.22% |
| Other Components | €540.48 Million | 320.21% |
| Total Equity | €168.79 Million | 100.00% |
DBV Technologies S.A. Competitors by Market Cap
The table below lists competitors of DBV Technologies S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Suzhou Medsys Tech Co Ltd
SHG:603990
|
$813.01 Million |
|
Anhui Sierte Fertilizer Industry Ltd Co
SHE:002538
|
$813.11 Million |
|
BMC Medical Co. Ltd. A
SHE:301367
|
$813.25 Million |
|
GurSel Turizm Tasimacilik Ve Servis Ticaret AS
IS:GRSEL
|
$813.29 Million |
|
Century Iron And Steel Industrial Co Ltd
TW:9958
|
$812.86 Million |
|
Jiangmen iDear-Hanyu Electrical Joint-Stock Co Ltd
SHE:300403
|
$812.67 Million |
|
INKON Life Technology Co Ltd
SHE:300143
|
$812.64 Million |
|
Xinjiang Qingsong Building Materials and Chemicals Group Co Ltd
SHG:600425
|
$812.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DBV Technologies S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 27,388,000 to 168,790,117, a change of 141,402,117 (516.3%).
- Net loss of 152,938,019 reduced equity.
- Share repurchases of 276,182,000 reduced equity.
- New share issuances of 276,182,000 increased equity.
- Other comprehensive income increased equity by 6,761,354.
- Other factors increased equity by 287,578,782.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-152.94 Million | -90.61% |
| Share Repurchases | €276.18 Million | -163.62% |
| Share Issuances | €276.18 Million | +163.62% |
| Other Comprehensive Income | €6.76 Million | +4.01% |
| Other Changes | €287.58 Million | +170.38% |
| Total Change | €- | 516.29% |
Book Value vs Market Value Analysis
This analysis compares DBV Technologies S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.94x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.59x to 1.94x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | €1.48 | €2.35 | x |
| 2012-12-31 | €5.42 | €2.35 | x |
| 2013-12-31 | €5.45 | €2.35 | x |
| 2014-12-31 | €11.33 | €2.35 | x |
| 2015-12-31 | €17.85 | €2.35 | x |
| 2016-12-31 | €10.95 | €2.35 | x |
| 2017-12-31 | €7.39 | €2.35 | x |
| 2018-12-31 | €5.73 | €2.35 | x |
| 2019-12-31 | €5.89 | €2.35 | x |
| 2020-12-31 | €4.66 | €2.35 | x |
| 2021-12-31 | €1.80 | €2.35 | x |
| 2022-12-31 | €2.51 | €2.35 | x |
| 2023-12-31 | €1.47 | €2.35 | x |
| 2024-12-31 | €0.28 | €2.35 | x |
| 2025-12-31 | €1.21 | €2.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DBV Technologies S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -90.61%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2713.59%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.38x
- Recent ROE (-90.61%) is below the historical average (-89.93%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -61.86% | -5744.65% | 0.01x | 1.34x | €-14.22 Million |
| 2012 | -33.22% | -7462.73% | 0.00x | 1.10x | €-28.89 Million |
| 2013 | -47.79% | -10619.61% | 0.00x | 1.14x | €-42.82 Million |
| 2014 | -20.80% | -11393.08% | 0.00x | 1.09x | €-56.12 Million |
| 2015 | -13.87% | -22115.85% | 0.00x | 1.07x | €-91.72 Million |
| 2016 | -47.16% | -1215.17% | 0.03x | 1.18x | €-153.14 Million |
| 2017 | -113.68% | -1525.17% | 0.05x | 1.37x | €-226.18 Million |
| 2018 | -136.93% | -1364.27% | 0.07x | 1.42x | €-243.58 Million |
| 2019 | -89.52% | -1327.17% | 0.05x | 1.41x | €-217.01 Million |
| 2020 | -77.65% | -1735.35% | 0.03x | 1.32x | €-220.88 Million |
| 2021 | -98.52% | -1713.54% | 0.04x | 1.48x | €-107.74 Million |
| 2022 | -49.51% | -2006.25% | 0.02x | 1.27x | €-115.75 Million |
| 2023 | -51.88% | -462.40% | 0.09x | 1.31x | €-86.74 Million |
| 2024 | -415.94% | -2744.35% | 0.06x | 2.40x | €-116.66 Million |
| 2025 | -90.61% | -2713.59% | 0.02x | 1.38x | €-169.82 Million |
Industry Comparison
This section compares DBV Technologies S.A.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $13,111,677
- Average return on equity (ROE) among peers: -94.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DBV Technologies S.A. (DBV) | €207.90 Million | -61.86% | 0.28x | $812.99 Million |
| Abionyx Pharma SA (ABNX) | $6.16 Million | -125.64% | 1.26x | $76.55 Million |
| Abivax SA (ABVX) | $40.58 Million | -434.26% | 4.06x | $8.28 Billion |
| Adocia (ADOC) | $45.85 Million | 16.61% | 0.53x | $90.58 Million |
| Aelis Farma SA (AELIS) | $898.00K | 63.92% | 30.53x | $16.32 Million |
| Biophytis S.A. (ALBPS) | $6.83 Million | -373.49% | 2.98x | $314.94K |
| Cellectis (ALCLS) | $6.40 Million | 0.00% | 0.20x | $209.45 Million |
| Advicenne (ALDVI) | $16.92 Million | -83.89% | 0.35x | $27.90 Million |
| Genoway (ALGEN) | $4.60 Million | 12.21% | 1.49x | $31.09 Million |
| Integragen (ALINT) | $3.93 Million | -21.94% | 1.20x | $1.00 Million |
| Medesis Pharma SA (ALMDP) | $-1.06 Million | 0.00% | 0.00x | $1.80 Million |
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobu… Read more